NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.07 | -1.49 | -0.16 |
| FCF Yield | -188.32% | -36.45% | -5.49% | -4.11% |
| EV / EBITDA | -0.08 | -2.00 | -10.14 | -18.57 |
| Quality | ||||
| ROIC | -98.49% | -61.37% | -32.99% | -33.24% |
| Gross Margin | 49.72% | 89.19% | 89.86% | -87.68% |
| Cash Conversion Ratio | 0.93 | 0.89 | 0.61 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -61.58% | -14.12% | -9.06% | -7.01% |
| Free Cash Flow Growth | 8.78% | -95.29% | 12.25% | -91.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.41 | 1.17 | 1.42 |
| Interest Coverage | 0.00 | -44.76 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -485.27 | -465.60 | -219.23 | 5.37 |